Form 10-Q

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such requirements for the past 90 days.

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes x No ¨

As of August 2, 2004 there were 16,334,705 shares of the registrant’s common stock outstanding.

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and in accordance with instructions to Article 10 of Regulation S-X. Accordingly, such consolidated financial statements do not include all of the information and disclosures required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal and recurring adjustments considered necessary for a fair presentation of Novoste’s financial results and condition have been included.

The operating results of the interim periods presented are not necessarily indicative of the results to be achieved for the year ending December 31, 2004. The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2003, included in Novoste’s 2003 Annual Report on Form 10-K filed with the Securities and Exchange Commission.

The consolidated financial statements include the accounts of Novoste Corporation and its wholly owned subsidiaries incorporated in August 1998 in the Netherlands, in December 1998 in Belgium, in February 1999 in Germany, in January 2000 in France and a dedicated sales corporation incorporated in the state of Florida in March 2002. Significant inter-company transactions and accounts have been eliminated.

Novoste sells its products with no right of return except in cases of product malfunction or shipping errors. On August 19, 2002, Novoste initiated a voluntary recall of the Beta-Rail^™ 3.5F Delivery Catheter (the “3.5F catheter”) inventory from its customers. The recall related to the discovery by Novoste of a small number of catheter tip separations in the 3.5F catheter product. An extensive evaluation and improvement program was initiated. A pre-market approval supplement was submitted to the U.S. Food and Drug Administration (FDA) on October 15, 2002, describing the improvements to the product and manufacturing processes and requesting approval for re-launch of the product. The FDA approved the re-launch on January 6, 2003.

In connection with the re-launch, Novoste exchanged 5.0F catheters for 3.5F catheters with a number of its customers. The exchange of these catheters was completed by September 2003 and all related reserves have been eliminated since that time. However, in the quarter ended June 30, 2003, Novoste had recorded a reserve of approximately $400,000 to recognize the 5.0F catheters purchased prior to June 30, 2003, that were expected to be returned in the future for exchange to 3.5F catheters.

Novoste’s significant accounting policies are included in the audited financial statements and notes thereto for the year ended December 31, 2003 included in Novoste’s 2003 Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Novoste accounts for grants of stock options and restricted stock under the recognition and measurement principles of Accounting Principles Board Option (APB) No. 25, Accounting for Stock Issued to Employees and related interpretations. The following table illustrates the effect on net income (loss) and earnings (loss) per share if Novoste had applied the fair value recognition provisions of Statement of Financial Accounting Standards (SFAS) No.123, Accounting for Stock-Based Compensation (in thousands, except per share amounts):

In January 2003, the FASB issued FASB Interpretation No. 46, Consolidation of Variable Interest Entities, an Interpretation of ARB No. 51, which requires a new approach in determining if a reporting entity should consolidate certain legal entities, including partnerships, limited liability companies, or trusts, among others, collectively defined as variable interest entities, or VIE’s. A legal entity is considered a VIE if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity that is the primary beneficiary must consolidate it. Even if a reporting entity is not obligated to consolidate a VIE, then certain disclosures must be made about the VIE if the reporting entity has a significant variable interest. Certain transition disclosures are required for all financial statements issued after January 31, 2003. The on-going disclosure and consolidation requirements are effective for all interim financial periods beginning after June 15, 2003. There is no impact of FIN 46 on our results of operations or financial condition.

Novoste evaluates long-lived assets in accordance with the provisions of SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets. SFAS No. 144 requires long-lived assets and certain identifiable intangibles to be reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If assets are impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.

Cash equivalents are comprised of certain highly liquid investments with maturities of less than three months. In addition to cash equivalents, Novoste has investments in commercial paper and other securities that are classified as short-term. All securities are considered as available-for-sale and reported at fair value, with the unrealized gains and losses reported as a component of Other Comprehensive Income (Loss) on the consolidated statements of shareholders’ equity. The amortized cost of debt securities in this category, if significant, is adjusted for amortization and included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities, of which there were none, would be included in interest income. Realized gains and losses are included in interest income and are determined on a specific identification basis. Interest and dividends on securities classified as available-for-sale are included in interest income.

Accounts receivable at June 30, 2004 and December 31, 2003 include receivables due from product sales and amounts due under lease and maintenance or service agreements to hospitals relating to radiation and transfer devices (See Note 7 to the unaudited consolidated financial statements). The carrying amounts reported in the consolidated balance sheets for accounts receivable approximate their fair value.

Novoste performs periodic credit evaluations of its customers’ financial condition and generally does not require collateral. Management records estimates of expected credit losses and returns of product sold. The income effect on the change in provision for doubtful accounts for the three-month period ended June 30, 2004, was $52,000, compared to $308,000 for the three-month period ended June 30, 2003. The change in provision for doubtful accounts for the six-month period ended June 30, 2004 was $108,000, compared to $256,000 for the six-month period ended June 30, 2003. The provision for doubtful accounts declined as aged accounts receivables balances decreased and collections were better than historically anticipated.

Inventories are stated at the lower of cost or market value on a first-in, first-out (FIFO) basis and are comprised of the following (in thousands):

Novoste retains ownership of the radiation source trains (RSTs) and transfer devices (TDs). Depreciation of the costs of these assets is taken over the estimated economic life using the straight-line method and is recorded in cost of sales. Depreciation begins at the time the Beta-Cath^™ System is placed into service. Novoste classifies the annual agreements with Novoste’s customers to license the use of radiation and transfer devices as operating leases. Income is recognized ratably over the length of the lease. At June 30, 2004, deferred revenue under these leases approximated $345,000, compared to $188,000 at December 31, 2003.

Radiation and transfer devices subject to operating leases, stated at cost, less accumulated depreciation, are comprised of the following (in thousands):

In June 2002, Novoste decided to phase out the 5.0F diameter catheter systems, resulting in an impairment charge of $5,065,000 and other related charges of $1,835,000 (See Note 14 to unaudited consolidated financial statements) to adjust the carrying value of these assets to their fair value. The remaining fair value was being amortized on a straight-line basis over the remaining useful life, then estimated to end March 31, 2003.

In August 2002, Novoste initiated a voluntary recall of 3.5F diameter catheters. To meet patient needs, the 5.0F catheter system was reinstalled in sites where the 3.5F catheter system had previously supplanted the 5.0F catheter system. Notwithstanding its return to widespread active use, the 5.0F catheter system was still expected to be replaced by a redesigned 3.5F catheter system early in 2003. The new design for the 3.5F catheter system was submitted to the FDA on October 15, 2002 and was approved by the FDA for re-launch on January 6, 2003.

At December 31, 2002, approximately $1,650,000 of unamortized costs for the 5.0F catheter assets remained. During the first quarter of 2003, despite the re-launch of the newly designed 3.5F catheter system in January, it became apparent that the 5.0F assets would be utilized beyond the previously estimated termination date, and in fact, remained in active use through December 31, 2003. Factors leading to an extended life included: (a) the time required to convert customers to 3.5F catheter systems following the recall, (b) the time required to complete training on the new 3.5F catheter replacement systems, and (c) allocations of 3.5F catheter systems to customer sites based on availability, customer preference and volume potential. Accordingly, the remaining value of the 5.0F catheter

assets was amortized through December 31, 2003, rather than through March 31, 2003, as previously estimated. The result of this change in the estimated useful life increased amortization expense by $413,000 for the second, third and fourth quarters in 2003. The expense impact of this change in estimate of useful lives of the 5.0F catheter in the six months ended June 30, 2004 and 2003 was $0 and $824,000, respectively, or $0.05 per share for the six months ended June 30, 2003.

Other assets consist mainly of license agreements and other intangibles. Novoste announced on April 22, 2004, that it had signed an asset purchase agreement with Guidant Corporation (Guidant) pursuant to which Novoste would acquire information regarding Guidant’s vascular brachytherapy business, including the customer list of Guidant in the United States and Canada. Under the terms of the agreement, during an established transition period, which is expected to be six months, Guidant and Novoste would jointly cooperate to transition the Guidant customers to Novoste products for any customer that wishes to continue vascular brachytherapy. Guidant would discontinue its vascular brachytherapy business in the United States and Canada over the six-month period. Additionally, Guidant has agreed to not compete in the vascular brachytherapy market in the United States and Canada for a period of five years. Novoste paid the sum of $2,500,000 to Guidant at the signing of the transaction and has agreed to pay an additional 5% on net sales to customers on the Guidant customer list that transition to Novoste’s products for a period of six months after the closing date of the Guidant transaction. After this six-month transition period, Novoste would pay an additional 5% on all U.S. and Canadian net sales of Novoste vascular brachytherapy products up to a maximum of $4,000,000. The initial payment is being amortized over twenty-four months.

Since August 2001, Novoste has had a relationship with a financial institution (lender). On May 27, 2004, Novoste replaced previous borrowing arrangements with a one-year agreement, which provides a $5,000,000 revolving line of credit and availability of letters of credit. The lender will issue letters of credit for Novoste’s account subject to certain limitations; however, all such letters of credit may not exceed $2,000,000 in the aggregate.

Under the revolving line of credit, Novoste may borrow an amount not to exceed the borrowing base as defined in the loan agreement, which is principally based on domestic accounts receivable. Interest on outstanding balances is payable on the first of each month, calculated on the outstanding balance, and accrues at a rate of the lender’s prime rate, which was 4.0% at June 30, 2004, plus 1%. To secure the payment and performance of all obligations when due, Novoste granted to the lender a first priority security interest in substantially all assets of Novoste.

At June 30, 2004 and December 31, 2003, Novoste had no outstanding borrowings or letters of credit.

SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information requires the reporting segment information based on the information provided to Novoste’s chief operating decision maker for purposes of making decisions about allocating resources and assessing performance. Novoste’s business activities are represented by a single industry segment, the manufacture and distribution of medical devices. For management purposes, Novoste is segmented into two geographic areas: United States and the Rest of the World (Europe, Canada, Asia and South America).

The following is a summary of selected financial information by reportable segment as of, and for the six months ended, June 30, 2004 and 2003 (in thousands):

Novoste’s total assets outside of the United States consist principally of cash and cash equivalents, accounts receivable and office equipment.

The following table sets forth the computation of basic and diluted earnings per share for the three-month and six-month periods ended June 30, 2004 and 2003 (in thousands, except per-share data):

The basic and diluted income or loss per share is computed based on the weighted average number of common shares outstanding. Weighted average shares outstanding, assuming dilution, includes the incremental shares that would be issued upon the assumed exercise of stock options. For the calculation of the three-month and six-month periods ended June 30, 2004, all stock options, representing approximately 2,757,000 shares of Novoste common stock, were excluded, as they would be anti-dilutive.

Of these, approximately 2,757,000 and 2,646,000 shares had an exercise price higher than the average price of Novoste’s common stock for the three-month and six-month periods ended June 30, 2004, respectively.

For the three-month and six-month periods ended June 30, 2003, approximately 1,241,000 and 1,258,000 shares, respectively, were excluded, as their exercise price was higher than the average price of Novoste’s common stock for these periods.

In March 2002, Novoste began commercial distribution of a newer, smaller Beta-Cath^™ System utilizing a 3.5F diameter catheter. Original plans were to introduce the product slowly; however, the smaller diameter system allowed physicians to provide better and more comprehensive treatment to their patients, and demand for the new product exceeded expectations and the first-year goal of installed sites was achieved in less than four months. While the older, larger 5.0F diameter Beta-Cath^™ Systems were still serviceable, during the second quarter of 2002, Novoste decided to concentrate marketing and development efforts on the 3.5F diameter Beta-Cath^™ System. Accordingly, Novoste evaluated the ongoing value of the 5.0F catheter systems that are equipped to be used with 30mm and 40mm radiation source trains. Based on this evaluation, Novoste determined that the transfer devices and radiation source trains, which were long-lived assets with a carrying amount of $8,600,000, were no longer recoverable and wrote them down to their estimated fair value of $3,500,000, and accrued $1,800,000 for related expenses, resulting in an impairment and other related charges of $6,900,000 for the second quarter of 2002. Fair value was based on expected future net cash flows to be generated by the transfer devices and radiation source trains during their remaining service lives, discounted at the risk-free rate of interest. The remaining fair value was amortized ratably over the estimated useful life of these assets.

On August 19, 2002, Novoste announced the recall of all 3.5F diameter catheter products (See Note 1 to the unaudited consolidated financial statements). As a result, demand for the 5.0F diameter system increased significantly to service the patients needing vascular brachytherapy. This increase demand provided cash flow in excess of the carrying value. Following the re-launch of a redesigned 3.5F catheter system in January 2003, the 5.0F systems continued to be utilized, but at a declining rate, as 3.5F systems returned to use. The revenue from the 5.0F systems continued to exceed carrying value and Novoste concluded that these assets would likely remain in active use through December 31, 2003. At June 30, 2004 no costs remained to be amortized for the 5.0F impaired assets.

In March 2004, Novoste announced a reduction in force to eliminate 84 positions to align Novoste’s staffing with current market conditions. Fifty-nine of the employees involved in the reduction terminated employment with Novoste during the three months ended March 31, 2004, whilst another 18 employees left during the three-months ended June 30, 2004. The remaining 7 employees will leave in the next quarter. The costs associated with terminated employees are included within operating expense in the unaudited consolidated statement of operations for the six months ended June 30, 2004.

Thirty-seven employees located in the U.S. were terminated during the quarter ended March 31, 2003, to align Novoste’s staffing with market conditions at the time. Termination costs of $254,000 were included in operating expense in the unaudited consolidated statement of operations for the six months ended June 30, 2003.

On December 23, 2002, Novoste signed a Distribution Agreement with Orbus Medical Technologies, Inc., (Orbus) a manufacturer of cardiology products. Novoste’s Chief Executive Officer, Mr. Al Novak, is also the Chairman of Orbus. During the first six months of 2004, Novoste purchased $82,000 of product from Orbus at normal commercial prices. As of June 30, 2004, Novoste has prepaid $84,000 for future product purchases. During the six months ended June 30, 2004, Novoste had net sales from this product line of $242,000, or 2% of total net revenues.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

In this Form 10-Q, “Novoste,” “the Company,” “we,” “us” and “our” refer to Novoste Corporation. Novoste^®, Beta-Cath^™, Corona^®, and the Novoste^® logo are trademarks of Novoste.

The forward-looking statements in this Form 10-Q are made under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended. Our operating results and financial condition have varied and may in the future vary significantly depending on a number of factors. Statements in this Form 10-Q which are not strictly historical statements, including, without limitation, statements regarding management’s expectations for future growth and plans and objectives for future management and operations, domestic and international marketing and sales plans, product plans and performance, research and development plans,

management’s assessment of market factors, as well as statements regarding our strategy and plans, constitute forward-looking statements that involve risks and uncertainties. In some cases these forward-looking statements can be identified by the use of words such as “may,” “will,” “should,” “expect,” “project,” “predict,” “potential” or the negative of these words or comparable words. The factors listed under “Certain Factors Which May Affect Future Results” in this Form 10-Q, among others, could cause actual results to differ materially from those contained in forward-looking statements made in this report and presented elsewhere by management from time to time. Such factors, among others, may have a material adverse effect upon our business, financial condition, and results of operations. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future global events or otherwise. Accordingly, you are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they are made.

Novoste’s discussion and analysis of its financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of our financial statements requires that we adopt and follow certain accounting policies. Certain amounts presented in the financial statements have been determined based upon estimates and assumptions. Although we believe that our estimates and assumptions are reasonable, actual results will differ and could be material.

We have included below a discussion of the critical accounting policies that we believe are affected by our more significant judgments and estimates used in the preparation of our financial statements, how we apply such policies and how results differing from our estimates and assumptions would affect the amounts presented in our financial statements. Other accounting policies also have a significant effect on our financial statements, and some of these policies also require the use of estimates and assumptions.

Revenue from the sale of products is recorded when an arrangement exists, delivery has occurred and services have been rendered, the seller’s price is fixed and determinable and collectability is reasonably assured. Novoste earns revenue from sales of catheters, stents, and from operating lease agreements to use the radiation source trains and transfer devices included in the Beta-Cath^™ System.

Novoste uses distributors in countries where the distributors’ experience and knowledge of local radiation and medical device regulatory issues is considered beneficial by Novoste’s management. Under the distributor arrangements, there are generally no purchase commitments and no provisions for cancellation of purchases. Novoste or the distributor may cancel the distributor agreements at any time.

Revenue from sales of catheters directly to hospitals is recognized upon shipment after the hospital has received a Beta-Cath^™ System and completed all licensing and other requirements to use the system. Novoste recognizes revenue from sales of catheters and stents at the time of shipment.

Novoste retains ownership of the radiation source trains and transfer devices and enters into either a lease or license agreement with its customers. Revenue recognition begins once an agreement has been executed, the system has been shipped, and all licensing and other requirements to use the system have been completed. The revenue is recognized ratably over the term of the agreement. Under the terms of the agreement signed with customers located in the United States, replacement and servicing of the radiation source train and transfer device is required at six-month intervals or twelve-month intervals, depending on the model of the device. This replacement and servicing cost is included in cost of sales as incurred. No other post-sale obligations exist.

Novoste sells its catheters with no right of return except in cases of product defect or shipping errors. In connection with the approval to re-launch the 3.5F catheter system on January 6, 2003, Novoste began exchanging with its customers 5.0F catheters for 3.5F catheters. A reserve was recorded against revenue for known returns and an estimate of unknown returns. The exchange of these catheters was completed by September 2003.

Novoste has invested significant resources to acquire radiation source trains and transfer devices that make up the Beta-Cath^™ System and offers multiple treatment options using either the standard length or the XL version of the 3.5F catheter, which can accommodate a 30mm, 40mm or 60mm train.

Novoste retains ownership of the radiation source trains and transfer devices that are used by customers. The costs to acquire, test and assemble these assets are recorded as incurred. Novoste has determined that based upon the manufacturer’s data, the estimated economic life for radiation source trains is one year, and transfer devices is three years. Accordingly, Novoste classifies these assets as long-term assets. Depreciation of the costs of these assets is included in cost of sales and is recognized over their estimated economic lives using the straight-line method. Depreciation begins at the time the Beta-Cath^™ System is placed into service. Valuation reserves are recorded for the balance of unamortized costs of transfer devices and radiation source trains that are on hand but not available for use by a customer.

During the second quarter of 2002, Novoste decided to concentrate marketing and development efforts on the 3.5F catheter system. Accordingly, Novoste evaluated the recoverability of the carrying value for 5.0F devices and other assets to determine if an impairment charge was necessary. Novoste performed this evaluation in accordance with the provisions of SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets. Based on this evaluation, Novoste determined that impairment and other related charges of $6,900,000 were warranted for the 5.0F assets for the second quarter of 2002 (See Notes 7 and 14 to unaudited consolidated financial statements). The 5.0F product line has now completed its practical service life and has no net book value at June 30, 2004.

Management will continue to evaluate its long-lived assets in accordance with SFAS No. 144.

Novoste uses the intrinsic value method for valuing its awards of stock options and restricted stock and recording the related compensation expense, if any, in accordance with APB No. 25, Accounting for Stock Issued to Employees, and related interpretations. Novoste grants stock options generally for a fixed number of shares to employees, directors, consultants and independent contractors with an exercise price equal to the fair market value of the shares at the date of grant. Compensation expense is recognized for increases in the estimated fair value of common stock for any stock options with variable terms. No compensation expense is recognized for stock option grants to employees for which the terms are fixed and the exercise price is equal to the fair market value of the shares at the date of the grant.

Novoste accounts for equity instruments issued to non-employees in accordance with the provisions of SFAS No. 123, Accounting for Stock-Based Compensation, and as amended by SFAS 148, Accounting for Stock-Based Compensation – Transition and Disclosure, and Emerging Issues Task Force Issue No. 96-18, Accounting for Equity Instruments that Are Issued to Other than Employees for Acquiring, or in Conjunction with Selling, Goods or Services.

Any compensation expense related to grants that do not vest immediately is amortized over the vesting period of the stock options using the straight-line method as that methodology most closely approximates the way in which the option holder vests in those options.

Novoste maintains allowances for doubtful accounts for the estimated losses resulting from the inability of our customers to make required payments. Most of our customers are hospitals located in the U.S.; however, some are distributors of our products in foreign countries or hospitals located in Europe. The amount recorded in the allowances is based primarily on management’s evaluation of the financial condition of the customers. If the financial condition of any customers deteriorates, additional allowances may be required. Allowances are also maintained for future sales returns and allowances based on an analysis of recent trends of product returns. Actual losses from uncollectible accounts are charged against the allowance when it is determined that the account cannot be collected.

Inventories are stated at the lower of cost or market value on a first-in, first-out (FIFO) basis. Provisions are recorded for excess or obsolete inventory equal to the cost of the inventory. Shelf-life expiration or replacement products in the marketplace may cause product obsolescence. If actual product demand and market conditions were less favorable than those projected by management, additional provisions might be required which would negatively impact operating profits. Novoste evaluates the adequacy of these provisions quarterly.

The challenges of the first quarter of 2004 continued into the second quarter of 2004. We expect that revenues have and will continue to be impacted by the rapid acceptance of drug-eluting stents in the medical community and their success in reducing in-stent restenosis since their introduction into the U.S. market in April 2003. We expect that sales of our vascular brachytherapy products will continue to decline in 2004 as compared to 2003, resulting in a future reduction in our revenues. To address the revenue decline, on April 22, 2004, Novoste concluded an asset purchase agreement with Guidant Corporation, pursuant to which Novoste acquired information regarding Guidant’s vascular brachytherapy business, including the customer list of Guidant for the United States and Canada as well as a five-year non-compete agreement. As a result, Novoste will be the sole provider of coronary brachytherapy products (See Note 8 to unaudited consolidated financial statements). As noted below, Novoste began an aggressive cost reduction program at the end of the first quarter and initiated restructuring of operations in the United States in order to bring expenses in line with lower revenues. In addition, in June 2004, Novoste introduced a new transfer device that has a service cycle of 12 months compared to a current 6 month cycle, which should favorably impact servicing costs. Also, during the second quarter of 2004, Novoste consolidated all U.S. operations into a single building, with the expectation of significantly lowering fixed costs for facilities.

Net sales decreased 67% in the second quarter and the first six months of 2004 from the same periods in the prior year due to the rapid acceptance of drug-eluting stents in the medical community. The U.S. customer base has dropped from approximately 400 sites to 360 sites since the second quarter of 2003. Also affecting the year-to-year comparison, during the second quarter of 2003, we experienced increased demand for the new 3.5F catheters that had been awaiting FDA approval, and we recognized $600,000 in revenues that had been deferred in anticipation of a catheter exchange upon relaunch of the redesigned 3.5F catheter. In addition to drug-eluting stents, we experienced increased direct competition from Guidant Corporation in the market for vascular brachytherapy products primarily in the first quarter of 2004, and to a lesser extent until late April 2004 when we completed the transaction with Guidant described above. Revenues from lease agreements have experienced a rebound during the second quarter of 2004 due to marketing initiatives to recover costs for servicing the transfer devices. Such revenues increased 22% over the first quarter of 2004 and were only 7% below the second quarter last year. Rest of World sales declined 10% in the second quarter of 2004 and 18% for the first six months of 2004 from the same period last year, due to the factors described above. Revenue from bare metal stents, a product line first licensed for international sale by Novoste in January 2003, has remained level due to a very competitive market in Europe. The completion of the Guidant transaction in the second quarter of 2004 had a very modest effect on second quarter revenues as conversion of accounts using the Beta-Cath^™ System required training and, in many cases, licensing for the use of radiation. We anticipate the conversion of a majority of the targeted former Guidant vascular brachytherapy customers to take place in the third quarter of 2004. As a result of our initiating these revenue programs for the transfer devices and radiation source trains, it remains unclear the extent to which new accounts from Guidant will convert to, and existing accounts will continue with Novoste’s vascular brachytherapy products.

In the quarter and six months ended June 30, 2004, cost of sales declined approximately 45% from the same periods of the prior year due to the significant reduction in revenues and the corresponding reduction of costs variable to sales. However, the reduction in total costs was not proportional to the decline in revenues due to the high fixed costs associated with the manufacturing and service operations.

The 80% and 78% decline in gross margin for the quarter and the first six months of 2004, respectively, was a result of the revenue decline coupled with relatively high fixed costs associated with manufacturing and service operations.

We believe significant factors impacting cost of sales and gross margins going forward include the utilization of catheters at the sites using the Beta-Cath^™ System. We believe that the Guidant transaction will result in additional sales, which will offset some of the fixed costs, and that the consolidation of operations into a single building will further reduce fixed costs. We also believe that depreciation of radiation devices will decline since the older 5.0F catheter system has completed its useful commercial life, and Novoste has moved to a single vascular brachytherapy system (3.5F) with the goal of lowering costs as maintenance of a second catheter system is eliminated.

At the end of the first quarter of 2004, Novoste announced a reduction in force, eliminating 84 positions across all functions. This reduction is expected to lower annual operating costs by approximately $6,000,000. During the first quarter of 2004, approximately 59 of the individuals left Novoste, with the remaining individuals leaving during the second and third quarters. Approximately $666,000 of severance-related costs is included in the operating costs for the six-months ended June 30, 2004.

The 76% decrease in research and development expenses for the second quarter and 52% decrease for the first six months of 2004, compared to the same periods of the prior year, is primarily in the area of clinical trials, with the suspension of the MOBILE (More Beta Radiation In Lower Extremities) trial in mid-2003 and the BRAVO (Beta Radiation for treatment of Arterial-Venous graft Outflow) trials in the first quarter of 2004. In addition, some engineering projects underway in early 2003 have been completed. A reduction in the number of projects and engineers supporting them also contributed to the decrease in expenses. Future research and development efforts will be focused on development of products, that serve the coronary and cancer disease markets and utilize the marketing and distribution strengths of Novoste. Some of these activities will be out-sourced on a project-by-project basis where specific skills can be obtained to meet the product development needs.

The 39% and 41% decrease in sales and marketing expense for the second quarter and six months, respectively, is due to reduced sales and marketing personnel, and to significantly lower variable expenses related to lower revenues, principally commissions and travel expenses. In addition, expenses for the prior year were elevated due to the January 2003 relaunch of the 3.5F catheter, which required extra training and travel to customer sites.

The 5% increase during the second quarter of 2004, compared to the same period of the prior year, for general and administrative expenses is mainly due to consulting fees associated with Sarbanes-Oxley compliance requirements and relocation expenses associated with consolidating all of U.S. operations into a single building. The 2% decrease for the first six months of 2004 is primarily due to the completion of computer systems consulting projects that had been in process for the six months of 2003, and ongoing cost reduction actions.

Other income for the second quarter of 2004 was $116,000 compared to $70,000 for the same period in the prior year. The increase was mainly due to the gain on sale of surplus equipment following the restructuring and consolidation into a single building during the current quarter. Other income for the six months of 2004 was $193,000 compared to $179,000 for the same period in the prior year. This net increase arose primarily from the gain on sale of surplus equipment.

Net income (loss) consisted of the following (in thousands, except per share amounts):

The decline in net income of $0.30 per share for the second quarter and $0.71 per share for the six months ended 2004, compared to the prior periods, was the result of significantly lower revenues, which were adversely impacted by the introduction of drug-eluting stents and the resulting decline in sales of our vascular brachytherapy products. The decline in operating income was partially offset by cost reduction initiatives during 2003 and in the first two quarters of 2004, but the drop in revenues could not be fully offset due to relatively high fixed costs associated with sales, manufacturing and service operations. Net income in the second quarter of 2003 was positively affected by recognition of $600,000 of revenue previously deferred in the first quarter of 2003 for catheter exchanges completed in 2003, following the relaunch of the 3.5F catheter in January 2003.

Net cash provided by (used in) operating activities consisted of the following (in thousands):

In the six months of 2004, $4,573,000 of cash was used to fund the period’s operating activities. This compares to $3,690,000 of cash generated in the same period of 2003. The changes in operating assets and liabilities are consistent with the decline in business volume. Depreciation of property and equipment has declined as a number of the capital assets installed when commercial production began in 2000 have reached, or are nearing, their depreciable life. This decline is offset somewhat by amortization of the customer list obtained from Guidant during the second quarter of 2004. Depreciation on radiation and transfer devices is lower due to the completion of the commercial life of the older 5.0F systems, and the full amortization of these assets, as well as many of the older 3.5F systems completing their amortizable life. Included in the change in operating assets for the first six months of 2004 was $2,196,000 generated from a reduction in receivables, compared to the same period of 2003 when $1,604,000 was used to fund the increased receivables associated with higher revenues from the relaunch of the 3.5F system in the first quarter of 2003.

Net cash provided by (used in) investing activities consisted of the following (in thousands):

Short-term investments have shifted to cash equivalents to fund operating losses, provide flexibility for future strategic investments and as a hedge against interest rate increases. Less cash was used to purchase property and equipment in the six months ended June 30, 2004 as compared to the same period of 2003, primarily due to the completion of in-house production facilities. Also, less cash was used to purchase radiation source trains and transfer devices compared to the same period in the prior year. This decrease in purchases reflects the deployment of devices to all active customer sites using vascular brachytherapy products, and the closure of inactive or unprofitable sites in 2004. In April 2004, Novoste purchased the vascular brachytherapy customer list from Guidant for $2,500,000, plus additional earned payouts, and has started the transition process of converting these accounts to the Novoste Beta-Cath^™ System (See Note 8 to unaudited consolidated financial statements).

During the quarter ended June 30, 2004, Novoste had no proceeds from the issuance of its common stock as a result of option exercises, compared to $227,000 in the second quarter of 2003 when stock options were exercised by employees. For the six months ended June 30, 2004 and 2003, proceeds were $7,000 and $655,000, respectively.

During the second quarter and first six months of 2004, Novoste received $8,000 and $8,000, respectively, for common stock purchased under the Employee Stock Purchase Program, compared to $62,000 and $62,000 for the same periods in 2003.

In August 2003, Novoste announced the extension of the stock buy-back program that originally began in August 2002, but had been suspended due to the 3.5F catheter recall. The plan was extended in September 2003 and the extension authorized the purchases of up to $7,000,000. No shares were repurchased during the quarter ended June 30, 2004. As of June 30, 2004, 185,400 shares had been repurchased in earlier periods for $725,000.

In May 2004, Novoste replaced its working capital loan agreement and obtained a $5,000,000 revolving line of credit with the same financial institution (lender). The one-year agreement will expire on May 26, 2005.

Novoste also has a letter of credit facility available under the revolving line of credit. The lender will issue or has issued letters of credit for Novoste’s account subject to certain limitations. Under the credit facility, all such issued letters of credit may not exceed $2,000,000 in the aggregate.

At June 30, 2004, Novoste had no outstanding borrowings or letters of credit (See Note 10 to unaudited consolidated financial statements).

At June 30, 2004, Novoste had commitments to purchase $5,578,000 of products and services, primarily components for the Beta-Cath^™ System.

On October 14, 1999, Novoste signed a development and manufacturing supply agreement with AEA Technologies QSA GmbH for a source of radioactive supply and for the development of a smaller diameter radiation source. The agreement provided for the construction of a production line that was placed into service in October 2002. In addition, the agreement provides for joint ownership of all intellectual property arising from the development work and requires that AEA manufacture vascular brachytherapy sources only for Novoste. Unless notification to terminate is provided two years prior to expiration, the agreement, which is effective until September 2006, automatically renews. Novoste expects to meet its contractual obligations under this agreement for 2004.

On June 20, 2001, Novoste amended its manufacturing and supply agreement with Bebig Isotopen-und Medizintechnik GmbH (Bebig), a German corporation, to manufacture and supply Novoste with radioactive sealed Strontium-90 seed trains. During each calendar year of the four-year contract, Novoste guarantees to pay to Bebig minimum annual payments of varying amounts that will total $7,500,000 over the term of the agreement and provide up to $250,000 for decommission expense of the production facility. All product purchases are credited against the annual guaranteed payment.

Novoste has entered into a license agreement with a physician pursuant to which he is entitled to receive a royalty on the net sales of the Beta-Cath^™ System (excluding consideration paid for the radioactive isotope), subject to a maximum aggregate payment of $5,000,000. Royalty fees paid to the physician were $54,000 and $163,000 for the three months ended June 30, 2004 and 2003, respectively, and $123,000 and $357,000 for the six months ended June 30, 2004 and 2003, respectively. As of June 30, 2004, aggregate payments of $2,080,000 have been made under the license agreement and have been expensed as costs of sales.

On January 30, 1996, Novoste entered into a license agreement whereby Emory University assigned its claim to certain technology to Novoste for royalties based on net sales (as defined in the agreement) of products derived from such technology, subject to certain minimum royalties. After the first commercial sale of royalty bearing products by Novoste, minimum royalties were due to Emory University in the following amounts: year 2 after the first commercial sale—$10,000; year 3—$15,000; year 4—$25,000; and years 5-10, $50,000 per year. The royalty agreement term is consistent with the life of the related patent and applies to assignments of the patent technology to a third party. Royalty fees paid to Emory University were $117,000 and $343,000 for the three months ended June 30, 2004 and 2003, respectively, and $259,000 and $729,000 for the six months ended June 30, 2004 and 2003, respectively, and have been expensed as costs of sales.

On April 22, 2004, Novoste signed an asset purchase agreement with Guidant pursuant to which Novoste would acquire information regarding Guidant’s vascular brachytherapy business, including the customer list of Guidant in the United States and Canada. Novoste paid the sum of $2,500,000 to Guidant at the signing of the transaction and has agreed to pay 5% on its net sales of all vascular brachytherapy products in the U.S. and Canada, up to an additional payment of $4,000,000 (See Note 8 to unaudited consolidated financial statements). Novoste has expensed $44,000 related to the additional payment for the three months ended June 30, 2004.

Novoste’s principal source of liquidity at June 30, 2004 consisted of cash, cash equivalents and short-term investments of $30,767,000, compared to $39,402,000 at December 31, 2003.

Novoste’s future liquidity and capital requirements will depend upon numerous factors, including the risks discussed at “Certain Factors Which May Affect Future Results”, below, and the following, among others: market demand for our products, especially with the acceptance of drug-eluting stents by our customers and the expected resulting decline in our revenues; the resources required to maintain a direct sales force in the United States and in the larger markets of Europe; the resources required to introduce enhancements to, and expansion of the Beta-Cath^™ System product line; the resources Novoste devotes to the development, manufacture and marketing of its products; resources expended to license or acquire new technologies; and the progress of Novoste’s clinical research and product development programs. Novoste may in the future seek to raise additional funds through bank facilities, debt or equity offering or other sources of capital. Additional financing, if, required, may not be available on satisfactory terms, or at all.

During the remainder of 2004, Novoste expects to allocate resources to continue product development and identify products complementary to applications for our Beta-Cath^™ technology, improve operating efficiencies for servicing transfer devices and transition the Guidant vascular brachytherapy business to the Novoste system. We expect that our existing cash reserves will be sufficient to fund any cash used by operations and meet our liquidity and capital spending needs at least through the end of 2004.

In connection with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, set forth below are cautionary statements identifying important factors that could cause actual events or results to differ materially from any forward-looking statements made by or on behalf of us, whether oral or written. We wish to ensure that any forward-looking statements are accompanied by meaningful cautionary statements in order to maximize to the fullest extent possible the protections of the safe harbor established in the Private Securities Litigation Reform Act of 1995. Accordingly, any such statements are qualified in their entirety by reference to, and are accompanied by, the following important factors that could cause actual events or results to differ materially from our forward-looking statements. For additional information regarding forward-looking statements, please read the “Cautionary Note Regarding Forward-Looking Statements” of this report.

We began to commercialize the Beta-Cath^™ System in the United States in November 2000. Approximately 98% of our revenues in the second quarter of 2004 were from sales of this system. We anticipate that for the foreseeable future we will be solely dependent on the continued success of the Beta-Cath^™ System; however, in the future we may be unable to manufacture the Beta-Cath^™ System in commercial quantities at acceptable costs or to demonstrate that the Beta-Cath^™ System is an attractive and cost-effective alternative or complement to other procedures, including coronary stents or drug-eluting stents. Because the Beta-Cath^™ System is our sole near-term product focus, we could be required to cease operations if new technology rendered vascular brachytherapy non-competitive. Our failure to continue commercialization of the Beta-Cath^™ System would have a material adverse effect on our business, financial condition and results of operations.

Wide Acceptance By The Medical Community of Drug-Eluting Stents Or Other New Technology Could Render Vascular Brachytherapy Generally Or The Beta-Cath^™ System In Particular Noncompetitive or Obsolete And, In Turn, Could Cause Our Revenues To Decline.

Several companies have developed additional ways to incorporate coatings and drugs into stent platforms as they pursue new innovations in stents. Along with new stent designs, these drug coatings represent revolutionary advancements in the performance of stents as defined by the rate of restenosis. Johnson & Johnson released its drug-eluting stent product in April 2003 and captured over 60% of the stent market with this single product. Boston Scientific Corporation launched its drug-eluting stents in March 2004. Medtronic and Guidant are expected to follow over the next two years, pending FDA approvals. We believe there are also studies being pursued by both Johnson & Johnson and Boston Scientific Corporation to use drug-eluting stents for the treatment of in-stent restenosis. With the rate of restenosis declining and new competitive technologies potentially reducing the in-stent restenosis market in which Novoste operates, we face significant challenge in maintaining our revenues through sales of vascular brachytherapy products.

Since the introduction of drug-eluting stents in April 2003, we have seen a wider acceptance of that product in the medical community and a decline in sales of our vascular brachytherapy products. We expect that sales of our vascular brachytherapy products will continue to decline, due to the rapid market acceptance of drug-eluting stents, resulting in a future reduction of our revenues.

We May Be Unable To Compete Effectively Against Larger Better Capitalized Companies.

Many of our competitors and potential competitors have substantially greater resources than we do and also have greater resources and expertise in the area of research and development, obtaining regulatory approvals, manufacturing and marketing. Our competitors and potential competitors may succeed in developing, marketing and distributing technologies and products that are more effective than those we will develop and market or that would render our technology and products obsolete or noncompetitive. We may be unable to compete effectively against such competitors and other potential competitors in terms of manufacturing, marketing, distribution, sales and servicing.

Our Patents And Proprietary Technology May Not Adequately Protect Our Proprietary Products

Our policy is to protect our proprietary position by, among other methods, filing United States and foreign patent applications. On November 4, 1997, we were issued United States Patent No. 5,683,345, on May 4, 1999, we received United States Patent No. 5,899,882 (which is jointly owned by us and Emory University) and on January 11, 2000, we received United States Patent No. 6,013,020, all related to the Beta-Cath^™ System. We also have several additional United States applications pending which cover other aspects of our Beta-Cath^™ System. The United States Patent and Trademark Office has indicated that certain claims pending in another United States application are allowable. With respect to the above-identified United States Patents and our other pending United States patent applications, we have filed, or will file in due course, counterpart applications in the European Patent Office and certain other countries.

Like other firms that engage in the development of medical devices, we must address issues and risks relating to patents and trade secrets. United States Patent No. 5,683,345 may not offer adequate protection to us because competitors may be able to design functionally equivalent devices that do not infringe that patent. Our patents could also be reexamined, invalidated or circumvented. Furthermore, claims under our other pending applications may not be allowed, or if allowed, may not offer any protection or may be reexamined, invalidated or circumvented. In addition, competitors may have or may obtain patents that will prevent, limit or interfere with our ability to make, use or sell our products in either the United States or international markets.

Compliance With Applicable Government Regulations: Ability To Successfully Complete Clinical Trials And Gain Market Approval For New Products

Our Beta-Cath^™ System is regulated in the United States and foreign jurisdictions as a medical device. As such, we are subject to extensive regulation by the FDA, by other federal, state and local authorities and by foreign governments. Noncompliance with applicable requirements can result in, among other things, fines, injunctions, civil penalties, recall or seizure of products, total or partial suspension of production, failure of the government to grant pre-market clearance or pre-market approval for devices, withdrawal of marketing approvals, a recommendation by the FDA that we not be permitted to enter into government contracts, and criminal prosecution. The FDA also has the authority to request repair, replacement or refund of the cost of any device manufactured or distributed.

The process of obtaining a pre-market approval and other required regulatory approvals can be expensive, uncertain and lengthy, and we may be unsuccessful in obtaining additional approvals to market new versions of the Beta-Cath^™ System or new indications for the Beta-Cath^™ System. The FDA may not act favorably or quickly on any of our submissions to the agency. We may encounter significant difficulties and costs in our efforts to obtain additional FDA approvals that could delay or preclude us from selling new products in the United States. Furthermore, the FDA may request additional data or require that we conduct further clinical studies, causing us to incur substantial cost and delay. In addition, the FDA may impose strict labeling requirements, onerous operator training requirements or other requirements as a condition of our market approval, any of which could limit our ability to market our systems. Labeling and marketing activities are subject to scrutiny by the FDA and, in certain circumstances, by the Federal Trade Commission. FDA enforcement policy strictly prohibits the marketing of FDA cleared or approved medical devices for unapproved uses. Further, if a company wishes to modify a product after FDA approval of a pre-market approval, including any changes that could affect safety or effectiveness, additional approvals will be required by the FDA. Such changes include, but are not limited to: new indications for use, the use of a different facility to manufacture the device, changes to manufacturing process, changes to the device package, changes in vendors that supply components, changes in design specifications and certain labeling changes. Failure to receive or delays in receipt of FDA approvals, including the need for additional clinical trials or data as a prerequisite to approval, or any FDA conditions that limit our ability to market our systems, could have a material adverse effect on our business, financial condition and results of operations.

The Hospitals With Which We Do Business May Be Delayed In Obtaining Or May Be Unable To Obtain The Licenses To Hold, Handle And Use Radiation That Are Required For Our Products.

Our business involves the import, export, manufacture, distribution, use and storage of Strontium-90 (Strontium/Yttrium), the beta-emitting radioisotope utilized in the Beta-Cath^™ System’s radiation source train. Hospitals in the United States are required to have radiation licenses to hold, handle and use radiation. Many of the hospitals and/or physicians in the United States have been required to amend their radiation licenses to include Strontium-90 prior to receiving and using our Beta-Cath^™ System. Depending on the state in which the hospital is located, its license amendment will be processed by and its use of the isotope will be regulated by either the state, in states that have agreed to such arrangement, with the United States Nuclear Regulatory Commission or directly by the NRC. Obtaining any of the foregoing radiation-related approvals and licenses can be complicated and time consuming.

In order for us to market the Beta-Cath^™ System in foreign jurisdictions, we must obtain and retain required regulatory approvals and clearances and otherwise comply with extensive regulations regarding safety and manufacturing processes and quality. These regulations, including the requirements for approvals or clearance to market and the time required for regulatory review, vary from country to country, and in some instances within a country. We may not be able to obtain regulatory approvals in such countries or may be required to incur significant costs in obtaining or maintaining our foreign regulatory approvals. Delays in receipt of approvals to market our products, failure to receive these approvals or future loss of previously received approvals could have a material adverse effect on our business, financial condition, and results of operations.

Some Of Our Activities May Subject Us To Risks Under Federal And State Laws Prohibiting “Kickbacks” And False Or Fraudulent Claims

A federal law commonly known as the Medicare/Medicaid anti-kickback law, and several similar state laws, prohibit payments that are intended to induce physicians or others either to refer patients or to acquire or arrange for or recommend the acquisition of health care products or services. While the federal law applies only to referrals, products or services for which payment may be made by a federal health care program, state laws often apply regardless of whether federal funds may be involved. These laws constrain the sales, marketing and other promotional activities of manufacturers of medical devices, such as us, by limiting the kinds of financial arrangements, including sales programs, with hospitals, physicians, laboratories and other potential purchasers of medical devices. Other federal and state laws generally prohibit individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent, or are for items or services that were not

provided as claimed. Since we may provide some coding and billing advice to purchasers of our products, and since we cannot assure that the government will regard any billing errors that may be made as inadvertent, these laws are potentially applicable to us. Anti-kickback and false claims laws prescribe civil and criminal penalties for noncompliance that can be substantial. Even an unsuccessful challenge could cause adverse publicity and be costly to respond to, and thus could have a material adverse effect on our business, results of operations and financial condition.

Product Liability Suits Against Us Could Result In Expensive And Time-Consuming Litigation, Payment Of Substantial Damages And Increases In Our Insurance Rates

The sale and use of our products could lead to the filing of product liability claims if someone were to allege that one of our products contained a design or manufacturing defect. A product liability claim could result in substantial damages and be costly and time-consuming to defend, either of which could materially harm our business or financial condition. We cannot assure that our product liability insurance would protect our assets from the financial impact of defending a product liability claim. Any product liability claim brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing insurance coverage in the future.

Our operating results have fluctuated significantly in the past on a quarterly basis. We expect that our operating results may fluctuate significantly from quarter to quarter and we may experience profits or losses in the future depending on a number of factors, including the extent to which (a) our products are able to compete effectively against drug-eluting stents (b) the timing and level of reimbursement for our products by third-party payors vary, and (c) other factors occur, many of which are outside our control.

We are highly dependent on the principal members of our management and scientific staff. Loss of our key personnel would likely impede achievement of our strategic and operational objectives. To be successful, we must retain key employees and attract additional qualified employees.

Our Lack Of Redundant Manufacturing Facilities and Suppliers Could Harm Our Business

We assemble all of our products at our facilities in Norcross, Georgia. The loss of these facilities would likely impede our manufacturing and sales efforts, which would materially and adversely affect our business and financial condition. Should this occur we would have to depend on outsourcing to produce our catheter products. Significant proportions of key components and processes relating to our products are purchased from a single source due to technology, availability, price, quality, and other considerations. Key components and processes currently obtained from single sources include isotopes, protective tubing for catheters, proprietary connectors, and certain plastics used in the design and manufacture of the transfer device. In the event a supply of a key single-sourced material or component was delayed or curtailed, our ability to produce the related product in a timely manner could be adversely affected. We attempt to mitigate these risks by working closely with key suppliers regarding our product needs and the maintenance of strategic inventory levels.

Issuance Of Preferred Stock May Adversely Affect The Rights Of Holders Of Common Stock Or Delay Or Prevent A Change Of Control Of The Company

In October 1996, our board of directors authorized 1,000,000 shares of Series A Participating Preferred Stock in connection with its adoption of a shareholder rights plan, under which we issued rights to purchase Series A Participating Preferred Stock to holders of the common stock. Upon certain triggering events, such rights become exercisable to purchase common stock (or, in the discretion of our board of directors, Series A Participating Preferred Stock) at a price substantially discounted from the then current market price of the common stock. Our shareholder rights plan could generally discourage a merger or tender offer involving our securities that is not approved by our board of directors by increasing the cost of effecting any such transaction and, accordingly, could have an adverse impact on shareholders who might want to vote in favor of such merger or participate in such tender offer.

Under our amended and restated articles of incorporation, our board of directors has the authority to issue up to 5,000,000 shares of preferred stock and to determine the price, rights, preferences and privileges of those shares without any further vote or action by our shareholders. The rights of the holders of our common stock will be subject to, and may be adversely affected by, the rights of the holders of any shares of preferred stock that may be issued in the future.

While we have no present intention to authorize any additional series of preferred stock, such issuance, while providing desirable flexibility in connection with possible acquisitions and other corporate purposes, could also have the effect of making it more difficult for a third party to acquire a majority of our outstanding voting stock. The preferred stock may have other rights, including economic rights senior to the common stock, and, as a result, the issuance thereof could have a material adverse effect on the market value of the common stock.

Certain Provisions Of Our Charter, By-laws And Florida Law May Delay Or Prevent A Change Of Control Of The Company

The amended and restated articles of incorporation provide for a classified board of directors, the existence of which could discourage attempts to acquire us. Additionally, in October 2002, our Board of Directors enacted two amendments to Novoste’s by-laws intended to strengthen the provisions of the by-laws that protect Novoste and its shareholders from unfair or coercive takeover tactics. In general, the amendments set forth certain notice requirements for shareholders when calling a special meeting of Novoste’s shareholders or submitting shareholder proposals (either a shareholder nomination of director or other business) at our annual meetings. In addition, the amended by-laws establish certain timing requirements for the setting of the record and meeting dates. We are also subject to the anti-takeover provisions of the Florida Business Corporation Act, the application of which may have the effect of delaying or preventing a merger, takeover or other change of control of Novoste and therefore could discourage attempts to acquire Novoste.

Derivative Financial Instruments, Other Financial Instruments, and Derivative Commodity Instruments

Novoste does not participate in derivative financial instruments, other financial instruments for which the fair value disclosure would be required under SFAS No. 107, Disclosures about Fair Value of Financial Instruments, or derivative commodity instruments. All of Novoste’s investments are in short-term, investment grade commercial paper, corporate bonds, certificates of deposit and U.S. Government and agency securities that are carried at fair value on our books.

Novoste’s cash equivalents and short-term investments are subject to market risk, primarily interest rate and credit risk. Novoste’s investments are managed by outside professional managers within investment guidelines set by Novoste. Such guidelines include security type, credit quality and maturity, and are intended to limit market risk by restricting Novoste’s investments to high credit quality securities with relatively short-term maturities.

At June 30, 2004, Novoste had $23,752,000 in cash equivalents with a weighted average interest rate of 1.04% and $7,015,000 in available-for-sale investments with a weighted average interest rate of 1.50%. With $23,752,000 in cash and short-term investments having less than 90 days to maturity and the balance of the portfolio investments that are in a stable investment rate environment, we believe the risk to principal associated with an increase in interest rates is minimal.

International revenues from Novoste’s foreign direct sales and distributor sales comprised 16% and 6% of total revenues for the six month periods ended June 30, 2004 and 2003, respectively. Sales to customers outside Europe and Canada are denominated in U.S. dollars, while European sales are denominated in Euros and British Pounds, and Canadian sales are in Canadian dollars. Novoste experienced an immaterial amount of transaction gains and losses for the six months ended June 30, 2004. Novoste is also exposed to foreign exchange rate fluctuations as the financial results of its Dutch, Belgian, German and French subsidiaries are translated into U.S. dollars in consolidation. As exchange rates vary, these results, when translated, may vary from expectations and adversely impact overall expected profitability. The net effect of foreign exchange rate fluctuations on Novoste during the six months ended June 30, 2004 was not material.

At June 30, 2004, Novoste’s total future purchase commitments include $3,216,000 denominated in Euros. This amount was derived from converting such purchase obligations using a June 30, 2004 conversion rate of $1.21 USD to 1 Euro. Some of these purchase obligations extend to 2006, and the actual settlement amount may be different from the amount presented, which is based on the conversion rate of June 30, 2004.

(a) Evaluation of Disclosure Controls and Procedures. As of the end of the period covered by this report, we carried out an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and Acting Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a–15(e) and 15d–15(e) of the Securities Exchange Act of 1934). Based on this evaluation, our Chief Executive Officer and Acting Chief Financial Officer have concluded that our disclosure controls and procedures are effective in timely notification to them of information we are required to disclose in our periodic Securities and Exchange Commission filings and in ensuring that this information is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and regulations.

(b) Changes in Internal Control. During the period covered by this report, there have been no significant changes in our internal control over financial reporting that have materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.

By a settlement agreement, dated June 4, 2004, Novoste settled a lawsuit filed in the United States District Court for the District of Connecticut against Scott Sacane, Durus Capital Management LLC and Durus Life Sciences Master Fund, Ltd, which suit sought recovery of profits made by the defendants from the purchases and sales of Novoste common stock that represented short-swing transactions under Section 16(b) of the Securities Exchange Act of 1934. Pursuant to the settlement agreement, the defendants filed amended Forms 4 with the Securities and Exchange Commission correcting disclosure of their purchases and sales of Novoste common stock and paid to Novoste the sums of money received from the purchases and sales of Novoste common stock which were short-swing profits under Section 16(b) of the Securities Exchange Act of 1934. The complaint filed by Novoste has been dismissed with prejudice and the settlement funds have been received by Novoste.

Novoste is subject to legal claims and assertions in the ordinary course of business. Except for the matters described above and in the annual report for the year ended December 31, 2003, filed with the Securities and Exchange Commission, we are not aware of any such claims or assertions that would have a material effect on Novoste.

Item 2. Changes in Securities, Use of Proceeds and Issuer Purchases of Equity Securities

(e) In August 2002, Novoste initiated a stock buy-back program. Under the program, we have the authority to purchase shares up to $7,000,000. The program may be suspended at any time and from time to time without prior notice. The program was suspended in connection with the August 2002 3.5F catheter recall and reinstated in September 2003. No shares were purchased during the first six months of 2004. As of June 30, 2004, 185,400 shares had been repurchased for $725,000.

At the annual meeting of shareholders of Novoste held on June 15, 2004 (the “2004 Annual Meeting”), Novoste shareholders took the following actions:

Each of the Class II Directors will serve for a three year term expiring at the annual meeting of shareholders of Novoste in 2007, or until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal. Election of the directors was determined by a plurality of the votes cast at the 2004 Annual Meeting. No other persons were nominated or received votes for election as Novoste’s directors at the 2004 Annual Meeting.

On April 22, 2004, we filed a current report on Form 8-K to disclose that we issued a press release announcing Novoste’s earnings for the quarter ended March 31, 2004. A copy of the release was furnished as an exhibit pursuant to Item 12 under Item 9 of such Form 8-K.

On May 5, 2004, we filed a current report on Form 8-K to disclose that we signed an asset purchase agreement with Guidant Corporation. A copy of the agreement was furnished as an exhibit pursuant to Item 5 of such Form 8-K.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NOVOSTE CORPORATION

/s/ SUBHASH C. SARDA

SUBHASH C. SARDA

Acting Chief Financial Officer

Principal Financial and Accounting Officer


Florida		59-2787476
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

4350 International Blvd. Norcross, GA		30093
(Address of Principal Executive Offices)		(Zip Code)


		PAGE NO.
	PART I. FINANCIAL INFORMATION

Item 1.	Consolidated Financial Statements

	Consolidated Balance Sheets as of June 30, 2004 (unaudited) and December 31, 2003	3

	Unaudited Consolidated Statements of Operations for the three months and six months ended June 30, 2004 and 2003	4

	Unaudited Consolidated Statements of Cash Flows for the six months ended June 30, 2004 and 2003	5

	Notes to Unaudited Consolidated Financial Statements	6-14

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14-25

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	25

Item 4.	Controls and Procedures	26

	PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	26

Item 2.	Changes in Securities, Use of Proceeds and Issuer Purchases of Equity Securities	26

Item 3	Defaults Upon Senior Securities	26

Item 4.	Submission of Matters to a Vote of Security Holders	27

Item 5.	Other Information	27

Item 6.	Exhibits and Reports on Form 8-K	28

SIGNATURES		30


	June 30, 2004			December 31, 2003
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	23,752		$	33,177
Short-term investments		7,015			6,225
Accounts receivable, net of allowance of $214 and $442, respectively		3,100			5,206
Inventory, net		2,369			2,439
Prepaid expenses and other current assets		528			480

Total current assets		36,764			47,527
Property and equipment, net		6,120			6,997
Radiation and transfer devices, net		5,276			6,304
Other assets		2,653			579

Total assets	$	50,813		$	61,407

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	691		$	1,492
Accrued expenses		5,011			6,483
Unearned revenue		345			188

Total current liabilities		6,047			8,163
Shareholders’ equity:
Preferred stock, $.01 par value, 5,000,000 shares authorized; no shares issued and outstanding		—			—
Common stock, $.01 par value, 25,000,000 shares authorized; 16,377,634 and 16,371,997 shares issued, respectively		164			164
Additional paid-in capital		187,901			187,880
Accumulated other comprehensive income		607			733
Accumulated deficit		(143,687	)		(135,302	)
Treasury stock, at cost, 42,929 shares		(172	)		(172	)
Unearned compensation		(47	)		(59	)

Total shareholders’ equity		44,766			53,244

Total liabilities and shareholders’ equity	$	50,813		$	61,407


	Three Months Ended June 30,						Six Months Ended June 30,
	2004			2003			2004			2003
Net sales	$	5,753		$	17,608		$	12,778		$	38,314
Cost of sales		3,464			6,318			7,338			13,386

Gross margin		2,289			11,290			5,440			24,928
Operating expenses:
Research and development		666			2,806			2,957			6,164
Sales and marketing		3,144			5,147			6,571			11,081
General and administrative		2,366			2,254			4,490			4,573

Total operating expenses		6,176			10,207			14,018			21,818

Income (loss) from operations		(3,887	)		1,083			(8,578	)		3,110
Interest income		75			70			162			183
Interest expense		—			(2	)		—			(9	)
Other income		41			2			31			5

Total other income		116			70			193			179

Net income (loss)	$	(3,771	)	$	1,153		$	(8,385	)	$	3,289

Net income (loss) per share - Basic	$	(0.23	)	$	0.07		$	(0.51	)	$	0.20

Weighted average shares outstanding - Basic		16,331			16,321			16,331			16,295
Net income (loss) per share - Diluted	$	(0.23	)	$	0.07		$	(0.51	)	$	0.19

Weighted average shares outstanding - Diluted		16,331			16,951			16,331			16,893


	Six Months Ended June 30,
	2004			2003
Cash flows from operating activities:
Net income (loss)	$	(8,385	)	$	3,289
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization of property, equipment and intangibles		1,499			1,765
Stock based compensation expense		18			72
Depreciation of radiation and transfer devices		2,113			4,748
Provision for doubtful accounts		(108	)		(256	)
Changes in assets and liabilities:
Accounts receivable		2,196			(1,604	)
Inventory		58			168
Prepaid expenses and other current assets		(49	)		122
Other assets		185			757
Accounts payable		(793	)		(968	)
Accrued expenses		(1,465	)		(2,620	)
Unearned revenue		158			(1,783	)

Net cash provided by (used in) operating activities		(4,573	)		3,690
Cash flows from investing activities:
Maturity/sale of short-term investments		5,619			9,486
Purchase of short-term investments		(6,409	)		(6,194	)
Purchase of property and equipment, net		(410	)		(698	)
Purchase of intangibles		(2,500	)		—
Purchase of radiation and transfer devices		(1,085	)		(1,613	)

Net cash provided by (used in) investing activities		(4,785	)		981
Cash flows from financing activities:
Proceeds from issuance of common stock		15			717
Repayment of capital lease obligations		—			(139	)

Net cash provided by financing activities		15			578
Effect of exchange rate changes on cash		(82	)		153

Net increase (decrease) in cash and cash equivalents		(9,425	)		5,402
Cash and equivalents at beginning of period		33,177			21,928

Cash and cash equivalents at end of period	$	23,752		$	27,330

Supplemental disclosure of cash flow information:
Cash paid for interest	$	—		$	9

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents


	Three Months Ended June 30,						Six Months Ended June 30,
	2004			2003			2004			2003
Net income (loss), as reported	$	(3,771	)	$	1,153		$	(8,385	)	$	3,289
Add: Total stock-based employee compensation expense included in net income (loss)		(8	)		10			18			72
Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards		(616	)		(1,070	)		(1,192	)		(2,343	)

Pro forma net income (loss)	$	(4,395	)	$	93		$	(9,559	)	$	1,018

Earnings (loss) per share:
Basic-as reported	$	(0.23	)	$	0.07		$	(0.51	)	$	0.20

Basic-pro forma	$	(0.27	)	$	0.01		$	(0.59	)	$	0.06

Diluted-as reported	$	(0.23	)	$	0.07		$	(0.51	)	$	0.19

Diluted-pro forma	$	(0.27	)	$	0.01		$	(0.59	)	$	0.06


	June 30, 2004			December 31, 2003
Raw materials	$	2,386		$	2,442
Work in process		119			124
Finished goods		1,033			1,115

Inventory, gross		3,538			3,681
Less: Inventory reserve		(1,169	)		(1,242	)

Inventory, net	$	2,369		$	2,439


	June 30, 2004			December 31, 2003
Furniture and fixtures	$	1,173		$	1,211
Office equipment		4,089			4,142
Laboratory equipment		892			991
Leasehold improvements		2,729			2,208
Production equipment		7,871			8,205

Property and equipment, gross		16,754			16,757
Less: Accumulated depreciation and amortization		(10,634	)		(9,760	)

Property and equipment, net	$	6,120		$	6,997


	June 30, 2004			December 31, 2003
Radiation and transfer devices, gross	$	23,641		$	25,554
Less: Accumulated depreciation		(18,365	)		(19,250	)

Radiation and transfer devices, net	$	5,276		$	6,304


	June 30, 2004		December 31, 2003
Salaries, wages and benefits	$	1,915	$	2,353
Radiation and disposals		1,212		1,598
Operating expenses & royalties		651		643
Professional fees		569		584
Clinical trials		292		783
Due to customers		248		310
Sales and use taxes		124		212

	$	5,011	$	6,483


Net sales

	United States			Rest of World			Consolidated
2004	$	10,790		$	1,988		$	12,778
2003		35,882			2,432			38,314

Net Income (Loss)

	United States			Rest of World			Consolidated
2004	$	(8,083	)	$	(302	)	$	(8,385	)
2003		3,414			(125	)		3,289

Long-lived assets

	United States			Rest of World			Consolidated
2004	$	13,124		$	624		$	13,748
2003		15,327			1,379			16,706

Total assets

	United States			Rest of World			Consolidated
2004	$	48,072		$	2,741		$	50,813
2003		61,984			4,347			66,331


	Three Months Ended June 30,					Six Months Ended June 30,
	2004			2003		2004		2003
Paid during period	$	307		$	58	$	666	$	254
Accrued from prior period		(111	)		—		—		—

Termination expense for the period	$	196		$	58	$	666	$	254


	Three Months Ended June 30,						Six Months Ended June 30,
	2004		2003		Increase (decrease)		2004		2003		Increase (decrease)
Net sales:
United States	$	4,831	$	16,583	(70.9	)%	$	10,790	$	35,882	(69.9	)%
Rest of World		922		1,025	(10.0	)%		1,988		2,432	(18.3	)%

Total net sales		5,753		17,608	(67.3	)%		12,778		38,314	(66.6	)%
Cost of sales		3,464		6,318	(45.2	)%		7,338		13,386	(45.2	)%

Gross margin	$	2,289	$	11,290	(79.7	)%	$	5,440	$	24,928	(78.2	)%


	For	Withheld
Alfred J. Novak	14,052,627	1,412,011
Judy Lindstrom	14,545,594	919,044


(a)	EXHIBIT NUMBER	DESCRIPTION
	3.1	Amended and Restated Articles of Incorporation of Registrant, filed on May 28, 1996. (1)

	3.2(a)	Copy of First Amendment to Amended and Restated Articles of Incorporation of Registrant filed with the Department of State of the State of Florida on November 1, 1996. (2)

	3.3	Copy of Third Amended and Restated By-Laws of Registrant dated May 5, 2003. (3)

	4.1	Form of Specimen Common Stock Certificate of Registrant. (4)

	4.17(a)	Amended and Restated Rights Agreement, dated as of July 29, 1999, between Novoste Corporation and American Stock Transfer and Trust Company, which includes as Exhibit B thereto the Form of Right Certificate. (5)

	4.17(b)	Amended and Restated Summary of Rights to Purchase Preferred Shares of Novoste Corporation. (5)

	4.20	Registration Rights Agreement dated as of March 28, 2000 by and between Novoste Corporation and the investors listed on the signature pages thereto. (6)

	31.1	Certification of Alfred J. Novak, Chief Executive Officer, pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

	31.2	Certification of Subhash C. Sarda, Acting Chief Financial Officer, pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

	32.1	Statements of Alfred J. Novak, Chief Executive Officer, and Subhash C. Sarda, Acting Chief Financial Officer, pursuant to 18 U.S.C. Section 1350.*